Cancer Research Articles

He is caring for patients at our FCS Ocala Cancer Center at 4945 SW 49th Place in Ocala, FL and our FCS Ocala office at 1630 SE 18th Street, Building 600 Suite 602, Ocala, FL.

FCS performed strongly in all areas of the survey. Rankings were highest for providers and communication with patients — both of which well exceeded statewide and national averages.

It will provide expanded treatment space for patients, with 18 exam rooms, 50 infusion chairs and on-site imaging, laboratory, pharmacy and care management services. Scheduled to open in November 2021, the 20,250-square-foot building will replace the two existing FCS clinic locations in Manatee County.

Scheduled to open in November 2021, the 20,250-square-foot building will replace the two existing FCS clinic locations in Manatee County.

Innovation proven to minimize potential side effects for prostate cancer patients who receive radiation therapy.

Fort Myers, Fla., Jan. 12, 2021  — Florida Cancer Specialists & Research Institute (FCS) welcomes Board-certified gynecologic oncologist Jessica Stine, MD. She is caring for patients at the FCS New Port Richey location at 8763 River Crossing Blvd., New Port Richey, FL and in Wesley Chapel at 2391 Oak Myrtle Lane, Wesley Chapel, FL.

Fort Myers, Fla., Jan. 12, 2021  — Florida Cancer Specialists & Research Institute (FCS) medical oncologist Michael McCleod, DO, FACOI, who practices in Fort Myers and Cape Coral, is co-author of a recently published study that evaluates and compares best supportive care (BSC) alone versus BSC plus nab-paclitaxel for squamous non-small-cell lung cancer (NSCLC). Published in the January 2021 issue of Clinical Lung Cancer, the study stated that while there have been “… significant treatment advances for patients with advanced non-small-cell lung cancer (NSCLC) …” in recent years, “… the number of treatment options for patients with squamous histologic features has lagged behind that for patients with non-squamous histologic features.”

This article examines cardiovascular adverse events in patients with non-metastatic prostate cancer.